Effect of introducing ethambutol and integrating drugs into fixed-dose tablets on mortality in tuberculosis patients
Transactions of The Royal Society of Tropical Medicine and Hygiene · 2026
DOI: 10.1093/trstmh/traf100 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transactions of The Royal Society of Tropical Medicine and Hygiene, 2026. Verfasst von Fredi Alexander Diaz-Quijano und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Laboratory of Causal Inference in Epidemiology - LINCE-USP, School of Public Health, University of São Paulo, São Paulo, …. Hauptthemen laut MEDLINE: Ethambutol, Antitubercular Agents, Isoniazid, Tuberculosis. Die Arbeit nennt 35 Literaturangaben. Gefördert von: National Council for Scientific and Technological Development.
Abstract (Originalsprache)
Background
In response to increasing primary resistance to isoniazid, the Brazilian Ministry of Health modified the tuberculosis (TB) treatment regimen at the end of 2009. The changes included adding ethambutol to the intensive phase, using fixed-dose combination tablets and adjusting isoniazid and pyrazinamide dosages. This study aimed to estimate the effect of the regimen change on all-cause mortality and, secondarily, on TB-specific mortality, treatment success and loss to follow-up.
Methods
We analysed cohorts of individuals ≥10 y of age who initiated TB treatment before (n = 145 528) and after (n = 161 264) the regimen change. Data were obtained from the national notifiable disease and mortality information systems. Missing data were imputed and effects were estimated using multilevel logistic regression models with states as the clustering level. Covariates were selected using a directed acyclic graph.
Results
The regimen change was not associated with all-cause mortality (relative risk [RR] 1.01 [95% confidence interval {CI} 0.98 to 1.04]) or TB-specific mortality (RR 0.98 [95% CI 0.95 to 1.02]). The treatment success rate was lower, and loss to follow-up was higher during the modified regimen period compared with the previous one. However, sensitivity analyses suggest that changes in the handling of transfers and missing outcome data may partly explain these findings.
Conclusion
We concluded that the modified regimen did not adversely affect survival among TB patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology, Laboratory of Causal Inference in Epidemiology - LINCE-USP, School of Public Health, University of São Paulo, São Paulo, SP 01246-904, Brazil.
- Health and Environment Surveillance Secretariat, Ministry of Health, Brasília, DF 70719-040, Brazil.
- Public Health Institute, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ 21941-598, Brazil.
ORCID-Profile: Fredi Alexander Diaz-Quijano
Förderung
- National Council for Scientific and Technological Development
Zitieren
APA
Diaz-Quijano, F. A., Bartholomay, P., Andrade, K. B., Pelissari, D. M., Arakaki-Sanchez, D., Costa, F. D., & Pinheiro, R. S. (2026). Effect of introducing ethambutol and integrating drugs into fixed-dose tablets on mortality in tuberculosis patients. Transactions of The Royal Society of Tropical Medicine and Hygiene. https://doi.org/10.1093/trstmh/traf100
Vancouver
Diaz-Quijano FA, Bartholomay P, Andrade KB, Pelissari DM, Arakaki-Sanchez D, Costa FD, et al. Effect of introducing ethambutol and integrating drugs into fixed-dose tablets on mortality in tuberculosis patients. Transactions of The Royal Society of Tropical Medicine and Hygiene. 2026. doi:10.1093/trstmh/traf100
BibTeX
@article{DiazQuijano2026,
author = {Diaz-Quijano, Fredi Alexander and Bartholomay, Patricia and Andrade, Kleydson Bonfim and Pelissari, Daniele Maria and Arakaki-Sanchez, Denise and Costa, Fernanda Dockhorn and Pinheiro, Rejane Sobrino},
title = {Effect of introducing ethambutol and integrating drugs into fixed-dose tablets on mortality in tuberculosis patients},
journal = {Transactions of The Royal Society of Tropical Medicine and Hygiene},
year = {2026},
doi = {10.1093/trstmh/traf100}
}
EUVIMED